ArticleObesity science & practice2026
Preventing Weight Regain After Glucagon-Like Peptide‑1 Therapy Discontinuation: A Pilot Randomized Controlled Trial.
Article in Obesity science & practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Objective: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective treatments for obesity, but discontinuation is common due to cost, insurance coverage limitations, side effects, patient preference, and other factors. Weight regain often occurs rapidly after cessation, yet few evidence-based strategies exist to support weight maintenance during this transition. This pilot randomized trial examined whether a digital wellness application or medically tailored meals (MTM) could mitigate weight gain during the first 4 months after GLP-1 cessation. Methods: In this pilot randomized trial, adults with prior GLP-1-induced weight loss were randomized to usual care, wellness application, or MTM at the time of GLP-1 cessation. Surveys assessed adherence and satisfaction (primary outcome) as well as exploratory outcomes, diet quality, and perceived health. Weight (exploratory) was measured monthly using validated Bluetooth scales. Results: Participants ( Conclusions: These findings suggest that structured support may attenuate early weight gain after GLP-1 cessation. Larger, more diverse trials with longer follow-up and clinical outcomes are needed to confirm results and clarify mechanisms.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.